Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

• Published in: Cancer immunology research Vol. 3; no. 11; p. 1248
• Main Authors: Heery, Christopher R, Singh, B Harpreet, Rauckhorst, Myrna, Marté, Jennifer L, Donahue, Renee N, Grenga, Italia, Rodell, Timothy C, Dahut, William, Arlen, Philip M, Madan, Ravi A, Schlom, Jeffrey, Gulley, James L
• Format: Journal Article
• Language: English
• Published: United States 01.11.2015
• Subjects: Adult; Aged; Brachyury Protein; Breast Neoplasms - immunology; Breast Neoplasms - therapy; Cancer Vaccines - administration & dosage; Cancer Vaccines - adverse effects; Cancer Vaccines - therapeutic use; CD4-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - immunology; Chordoma - immunology; Chordoma - therapy; Colorectal Neoplasms - immunology; Colorectal Neoplasms - therapy; Dose-Response Relationship, Immunologic; Female; Fetal Proteins - immunology; Humans; Immunity, Cellular; Male; Middle Aged; Neoplasm Proteins - immunology; Saccharomyces cerevisiae - immunology; T-Box Domain Proteins - immunology; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - adverse effects; Vaccines, Inactivated - therapeutic use

The nuclear transcription factor brachyury has previously been shown to be a strong mediator of the epithelial-to-mesenchymal transition (EMT) in human carcinoma cells and a strong negative prognostic factor in several tumor types. Brachyury is overexpressed in a range of human carcinomas as well as...